Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics Inc.

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.

Flagship Pioneering

Casdin Capital

Invus

Irving Investors

Happy New Year from all of us at Foghorn! As we kick off 2024, we look forward to the year ahead as we continue to advance our mission to transform patient’s lives by correcting abnormal gene expression. #biotechnology #innovation #oncology

Check out photos of our Foghorn team, who had fun swapping surprises at our end of year holiday party. From all of us at Foghorn, wishing everyone a healthy and happy holiday season! #HappyHolidays

That's a wrap on the 65th Annual American Society of Hematology Meeting! Our team enjoyed coming together with the scientific community to present data and talk about our novel approach to modulating the chromatin regulatory system. Read all of our recent data presentations from #ASH23 and beyond: https://bit.ly/3GJ2vkZ

Martin (Murphy) Hentemann Kathleen Healy Caroline Almon #biotechnology #innovation #TPD

Meet Alexia Kalogeropulou, one of our brilliant scientists at Foghorn. Alexia shares why she loves the collaborative culture that enables us to advance our mission to transform the lives of people living with a wide spectrum of diseases. #LifeAtFoghorn #WomenInSTEM #biotechnology

Join us at the 2nd Annual TPD Assay Development & Screening Summit, where our Head of #DrugDiscovery, Marina Nelen, will be part of a panel to discuss high-throughput screening approaches and applications of assay techniques to degrader triage and profiling. See the agenda: https://ow.ly/J9Bh50QfwVc
#biotechnology #innovation #proteindegradation

We’re looking forward to the 65th American Society of Hematology Annual Meeting and Exposition, where clinical data from the Phase 1 dose-escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented. Learn more: https://ow.ly/wc3q50Qel4h
#ASH23

We know that our people are the key to our success, which is why we embrace a people first culture. Our culture is just one reason that Madeleine Henley was drawn to Foghorn. Learn more about our culture: https://ow.ly/Ca4050Qe2u8 

#LifeAtFoghorn #WomenInSTEM

Happy #Thanksgiving to all! Today, we are especially thankful for the incredible Foghorn team and their unwavering commitment to our mission of transforming lives across a wide spectrum of diseases. #biotechnology #innovation

Last week, we had the pleasure of joining other leading experts in the chromatin and epigenetics field during #Epi2023, where Dave Lahr gave a presentation on our preclinical work during a session on the nucleosome and chromatin remodeling. Find all our recent data presentations here: https://lnkd.in/gUtu9Wfi

#biotechnology #oncology #innovation

Congratulations to this year's recipients of the 2023 Paul Marks Prize for Cancer Research, including our scientific co-founder, Cigall Kadoch! This award underscores the important work being done at Foghorn to address breakdowns in the chromatin regulatory targets to advance novel treatments in cancer and beyond. #oncology #cancerresearch #innovation

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	2.01M -	3.44M 70.75%	3.68M 7.01%	3.82M 3.78%	5.41M 41.76%	6.26M 15.63%
accumulated other comprehensive income loss	-616K -		-7K -	-10K 42.86%	-3.99M 39,760%	-826K 79.28%
cash and cash equivalents	40.02M -	14.98M 62.57%	92.80M 519.42%	101.14M 8.99%	345.80M 241.91%	80.34M 76.77%
cash and short term investments	40.02M -	14.98M 62.57%	185.77M 1,140.04%	154.29M 16.95%	345.80M 124.12%	234.06M 32.31%
common stock			4K -	4K 0%	4K 0%	4K 0%
deferred revenue		3.25M -	2.02M 37.74%	28.32M 1,299.06%	336.82M 1,089.46%	34.55M 89.74%
deferred revenue non current			12.55M -	322.73M 2,472.37%	304M 5.80%	268.12M 11.80%
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt	7.03M -	11.12M 58.16%	78.02M 601.76%	51.34M 34.19%	45.54M 11.30%	36.55M 19.72%
long term investments						1.71M -
net debt	-32.99M -	1.65M 105.00%	-10.80M 755.28%	-42.80M 296.37%	-294.29M 587.53%	-35.26M 88.02%
net receivables				300M -
other assets						1 -
other current assets	383K -	1.36M 255.87%	4.92M 260.75%	5.27M 7.24%	5.60M 6.22%	6.12M 9.34%
other current liabilities	1.45M -	450K 68.86%	9.16M 1,935.78%	9.56M 4.38%	-11.38M 219.05%	9.11M 180.01%
other liabilities
other non current assets	566K -	1.74M 208.13%	2.58M 47.65%	4.13M 60.50%	9.69M 134.41%	1.11M 88.49%
other non current liabilities	71.84M -	86.59M 20.53%		143K -	-281.59M 197,013.29%
othertotal stockholders equity	4.35M -	6.12M 40.66%	53.53M 774.71%	361.13M 574.61%	377.23M 4.46%	395.20M 4.76%
preferred stock			255.59M -
property plant equipment net	2.09M -	3.71M 77.66%	62.33M 1,578.75%	56.08M 10.03%	49.40M 11.92%	42.91M 13.13%
retained earnings	-43.01M -	-94.14M 118.88%	-162.94M 73.09%	-264.26M 62.18%	-373.14M 41.20%	-471.56M 26.38%
short term debt		5.51M -	3.98M 27.78%	6.99M 75.68%	5.97M 14.64%	8.52M 42.68%
short term investments			92.97M -	53.15M 42.83%	293.58M 452.34%	153.72M 47.64%
tax assets
tax payables						674K -
total assets	43.06M -	22.34M 48.11%	255.59M 1,044.01%	519.77M 103.36%	404.88M 22.10%	285.92M 29.38%
total current assets	40.40M -	16.89M 58.21%	190.69M 1,029.33%	459.56M 141.00%	345.80M 24.75%	240.18M 30.54%
total current liabilities	3.46M -	12.65M 265.77%	18.85M 48.96%	48.69M 158.37%	336.82M 591.74%	58.44M 82.65%
total debt	7.03M -	16.63M 136.58%	82.00M 393.09%	58.33M 28.86%	51.51M 11.70%	45.07M 12.49%
total investments			92.97M -	53.15M 42.83%	293.58M 452.34%	155.43M 47.06%
total liabilities	82.33M -	110.36M 34.04%	109.41M 0.86%	422.90M 286.54%	404.77M 4.29%	363.11M 10.29%
total liabilities and stockholders equity	43.06M -	22.34M 48.11%	255.59M 1,044.01%	519.77M 103.36%	404.88M 22.10%	285.92M 29.38%
total non current assets	2.66M -	5.46M 105.46%	64.91M 1,089.43%	60.21M 7.23%	59.09M 1.87%	45.73M 22.59%
total non current liabilities	78.87M -	97.71M 23.88%	90.56M 7.31%	374.21M 313.21%	67.95M 81.84%	304.67M 348.37%
total stockholders equity	-39.27M -	-88.02M 124.11%	146.19M 266.09%	96.87M 33.73%	112K 99.88%	-77.19M 69,019.64%

COM:FOGHORNTX

Foghorn Therapeutics Inc.

Last Close

7.86

21/11 21:00

Market Cap

265.58M

Beta: -

Volume Today

69.99K

Avg: -

Preview